Context Therapeutics Stock (CNTX): Why The Price Surged Today

By Amit Chowdhry ● Dec 9, 2021
  • The stock price of Context Therapeutics Inc (NASDAQ: CNTX) increased by over 30% during intraday trading today. This is why it happened.

The stock price of Context Therapeutics Inc (NASDAQ: CNTX) increased by over 30% during intraday trading today. Investors are responding positively to a key data readout based on the company’s ongoing clinical trials for the lead asset onapristone extended-release (ONA-XR) in patients with metastatic breast cancer, according to Seeking Alpha.

The presents will occur at the 2021 San Antonio Breast Cancer Symposium (SABCS) – which is being held virtually in San Antonio, Texas. And a poster session is scheduled for later today and this will include data from the Phase 2 SMILE study for ONA-XR and fulvestrant combination in a certain group of patients with metastatic breast cancer. Plus another poster session be based on data from a Phase 1b study for onapristone ER in combination with letrozole and palbociclib.

“We are pleased that ONA-XR data from multiple stages of breast cancer will be presented at SABCS including the first clinical data from the ONAWA trial, sponsored by the Spanish cancer research group SOLTI, of ONA-XR in early-stage breast cancer and updates from two ongoing clinical trials of ONA-XR in metastatic breast cancer. We look forward to connecting with the oncology community at SABCS, to discuss advancements in breast cancer and further highlight the potential of ONA-XR to make a meaningful impact in the lives of people living with breast cancer,” said Martin Lehr, CEO of Context Therapeutics, in a statement a few weeks ago.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.